The update was requested by the FDA based on data supporting the significant LDL-C lowering abilities of PCSK-targeting therapies.

Aceclidine is a cholinergic muscarinic agonist that causes contraction of the iris sphincter muscle, thereby creating a pinhole effect that extends focus depth to improve vision in presbyopia.